---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021199"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:35:08.675204+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q1 net loss $30.2M ($0.74/sh); cash $256.2M; evorpacept trials advance

## Summary
- GAAP net loss $30.2M vs $24.5M YoY; non-GAAP net loss $23.8M vs $19.0M.
- Cash, equivalents and investments $256.2M; runway through mid-2025 with $40M term loan available.
- R&D expenses $24.8M, up 45% YoY driven by more active trials and manufacturing.
- Entered clinical collaboration with Sanofi to test evorpacept + SARCLISA in relapsed/refractory multiple myeloma.
- Top-line data expected H2 2023 from ASPEN-06 (gastric cancer) and ASPEN-02 (MDS) trials.

## SEC filing metadata
- accession: 0000950170-23-021199
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/0000950170-23-021199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/alxo-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021199
- JSON: https://secwatch.observer/filing/0000950170-23-021199.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021199.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/0000950170-23-021199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.